Differently designed trials so difficult to compare. They don't mention the liver fibrosis scores of the subjects, and after genotype this is in fact the most important predictor of response in HCV (they could have recruited only those without cirrhosis, and made their results look better) - in the 'real world' I suspect that the potency is not greatly different to telaprevir. Still does not overcome the effect of an IL-28B T allele (the CT and TT patients did worse). The 4 times daily dosing is a weakness - I haven't met too many HCV patients who'd reliably take pills 4 times a day, and in the 'real world' this might significantly reduce its efficacy.
BIT225 really needs testing in a 'hard to treat' group of patients with IL-28B allele stratification to see whether it offers advantages over what protease and polymerase inhibitors give.
- Forums
- ASX - By Stock
- BIT
- protease inhibitor recieves fast track
protease inhibitor recieves fast track, page-5
Featured News
Add BIT (ASX) to my watchlist
|
|||||
Last
2.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $23.46M |
Open | High | Low | Value | Volume |
2.5¢ | 2.6¢ | 2.5¢ | $23.83K | 953.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 2.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.5¢ | 5000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 0.024 |
4 | 3527246 | 0.023 |
3 | 625000 | 0.022 |
1 | 250000 | 0.021 |
3 | 250000 | 0.020 |
Price($) | Vol. | No. |
---|---|---|
0.025 | 5000 | 1 |
0.026 | 47379 | 2 |
0.027 | 161989 | 2 |
0.028 | 400000 | 2 |
0.029 | 305600 | 3 |
Last trade - 15.15pm 22/08/2024 (20 minute delay) ? |
Featured News
BIT (ASX) Chart |
The Watchlist
SS1
SUN SILVER LIMITED
Gerard O'Donovan, Executive Director
Gerard O'Donovan
Executive Director
SPONSORED BY The Market Online